About this Research Topic
This Research Topic focuses on studies that investigate and discuss:
1) Epidemiologic evidence linking the presence of endocrine-metabolic diseases (obesity, metabolic syndrome, etc.) and the development and/or progression cancer.
2) The prevention and treatment of cancer pathologies investigating approaches based on the modulation of metabolic diseases.
3) The molecular and cellular determinants in the interplay between endocrine-metabolic disturbances and cancer .
4) The endocrine and/or metabolic alterations linked to the development and progression of cancer.
5) The impact of endocrine-metabolic determinants on the modulation and adaptation of cancer cell metabolism and/or microenvironment.
6) Novel approaches and/or animal models for the study of the interplay between metabolic dysregulations and cancer.
7) The potential antitumor effects that different metabolic drugs commonly used to treat endocrine-related diseases [such as biguanides (e.g. metformin), statins (e.g. simvastatin), etc.] exert in different endocrine-related tumors and cancer.
The aim of this Research Topic is to provide an overview of the pathophysiological interrelationship between obesity, metabolic diseases, and cancer. To this end, we would like to welcome submissions in the form of Reviews and/or Original Research articles presenting cutting-edge scientific advances on the potential interplay between endocrine-metabolic disorders, such as obesity and metabolic syndrome, and cancer development and progression, including novel data in relevant animal models and humans.
Keywords: Cancer, Obesity, Endocrine-related tumors, metabolism, Diabetes, drug resistance mechanisms, cell signaling, metabolic agents, inflammation, tumor microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.